| 3.65 0 (0%) | 02-06 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.32 | 1-year : | 5.04 |
| Resists | First : | 3.7 | Second : | 4.32 |
| Pivot price | 3.62  |
|||
| Supports | First : | 3.28 | Second : | 3.02 |
| MAs | MA(5) : | 3.64 |
MA(20) : | 3.54 |
| MA(100) : | 4.3 |
MA(250) : | 4.36 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 88.1 |
D(3) : | 87.2 |
| RSI | RSI(14): 59.5 | |||
| 52-week | High : | 7.55 | Low : | 2.29 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ RVNC ] has closed below upper band by 43.2%. Bollinger Bands are 69.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.66 - 3.67 | 3.67 - 3.69 |
| Low: | 3.61 - 3.63 | 3.63 - 3.64 |
| Close: | 3.62 - 3.65 | 3.65 - 3.68 |
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing DaxibotulinumtoxinA in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Thu, 06 Mar 2025
REVANCE ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Fri, 28 Feb 2025
Revance Therapeutics, Inc. (RVNC) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Mon, 24 Feb 2025
Class Action Filed Against Revance Therapeutics, Inc. (RVNC) Seeking Recovery for Investors - Contact Levi & Korsinsky - ACCESS Newswire
Thu, 20 Feb 2025
The Gross Law Firm Announces the Filing of a Securities - GlobeNewswire
Tue, 18 Feb 2025
Deadline Alert: Revance Therapeutics, Inc. (RVNC) Investors - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 104 (M) |
| Shares Float | 91 (M) |
| Held by Insiders | 8.5 (%) |
| Held by Institutions | 87.4 (%) |
| Shares Short | 4,510 (K) |
| Shares Short P.Month | 9,770 (K) |
| EPS | -3.34 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.55 |
| Profit Margin | -71.8 % |
| Operating Margin | -53.9 % |
| Return on Assets (ttm) | -24.4 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 10.6 % |
| Gross Profit (p.s.) | 0.99 |
| Sales Per Share | 2.46 |
| EBITDA (p.s.) | -1.8 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -191 (M) |
| Levered Free Cash Flow | -168 (M) |
| PE Ratio | -1.1 |
| PEG Ratio | 0 |
| Price to Book value | -2.36 |
| Price to Sales | 1.48 |
| Price to Cash Flow | -2 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|